Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com downgraded shares of Abeona Therapeutics from a hold rating to a sell rating in a report on Tuesday.

Abeona Therapeutics Stock Down 53.7 %

Shares of NASDAQ:ABEO opened at $3.41 on Tuesday. The company has a market cap of $93.26 million, a price-to-earnings ratio of -1.32 and a beta of 1.49. The firm’s 50-day simple moving average is $7.49 and its 200-day simple moving average is $5.65. Abeona Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, research analysts forecast that Abeona Therapeutics will post -1.83 EPS for the current year.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. boosted its holdings in Abeona Therapeutics by 84.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock worth $13,682,000 after buying an additional 1,488,834 shares in the last quarter. AIGH Capital Management LLC raised its position in Abeona Therapeutics by 77.7% during the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after acquiring an additional 496,278 shares during the last quarter. Citigroup Inc. raised its position in Abeona Therapeutics by 125.0% during the third quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock worth $1,894,000 after acquiring an additional 250,000 shares during the last quarter. Barclays PLC raised its position in Abeona Therapeutics by 100.0% during the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after acquiring an additional 185,638 shares during the last quarter. Finally, Worth Venture Partners LLC raised its position in Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after acquiring an additional 121,969 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.